

## **IPSOGEN part of a 2.9 M€ granted European project dedicated to breast and colon cancer biomarker research - 'COBRED project'**

Marseille, France, May 24, 2007 – IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6<sup>th</sup> Framework Programme.

**COBRED** project aims at discovering breast cancer (BC) and colon cancer (CRC) biomarkers for patient follow-up (monitoring markers) by exploiting the capacity of 3 state-of-the-art high-throughput technologies in an integrated systems biology approach. In addition to **Ipsogen**, the consortium comprises 2 other biotechnology firms (**BioSystems International**, coordinator – Paris, France; **Biocrates** – Innsbrück, Austria), 2 large comprehensive cancer centres (**Institut Curie** - Paris, France; **Institut Gustave Roussy**, - Villejuif, France) and 3 academic partners (**University of Debrecen**, Hungary; **University of Innsbrück**, Austria; **University of Tartu**, Estonia); the consultancy firm **ARTTIC** (Paris, France) will support the consortium for project management.

After 3 years, COBRED will deliver a set of biomarker candidates verified in preclinical studies, ready for large scale clinical validation and further development for commercialisation by the respective biotechnology firms. Furthermore COBRED will have demonstrated the potential to explore consolidated data resulting from different high-throughput technologies and clinical profiles with advanced data mining technologies for enhanced biomarker discovery. Although within the project scope COBRED focuses on biomarkers for follow-up diagnostics, it has the potential to evolve to an early cancer detection & screening tool.

*"Ipsogen has already been successful in leveraging European academic R&D and clinical networks in blood cancers (e.g. Europe Against Cancer and European LeukemiaNet) for discovery and validation of follow-up biomarkers. With the COBRED project we are now building a powerful research platform, aggregating major technologies and clinical expertise with the exciting goal of defining new tools for the monitoring of Breast and Colon cancer treatments"* said Vincent Fert, Ipsogen's Chief Executive Officer.

This work is supported by funding under the Sixth Research Framework Programme of the European Union, Project COBRED (LSHB-CT-2007-037730).

### **About Ipsogen**

IPSOGEN is a gene-based diagnostic company committed to identify cancer biomarkers and improve disease management of cancer patients. IPSOGEN addresses two key markets: (i) The molecular diagnosis of cancer (i.e. leukaemia, lymphoma, breast cancer) to provide innovative diagnostic tools to clinical centres; (ii) The support of anti-cancer drug development with a wide range of molecular services offered to the pharmaceutical industry in the context of preclinical and clinical studies. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its products worldwide.

*This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ*

*materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.*

## **CONTACTS**

Ipsogen: Fabienne Hermitte, Chief Scientific Officer - Tel +33 4 91293090 - [hermitte@ipsogen.com](mailto:hermitte@ipsogen.com)

### **Global Headquarters**

Ipsogen  
Luminy Biotech Entreprises  
Case 923 - 163 Ave de Luminy  
13288 Marseille  
France

Tel: +33 4 91 29 30 90  
Fax: +33 4 91 29 30 99

[infos@ipsogen.com](mailto:infos@ipsogen.com)

### **North America - Oncodiagnostics**

Ipsogen, Inc  
83 Maple Avenue  
Windsor  
Connecticut 06095  
USA

Tel: +1 860 298 0234  
Fax: +1 860 298 8586

[infos@ipsogen.com](mailto:infos@ipsogen.com)